About
Gut microbiome modifiers
Areas of Focus
Categories
Biologics & BiopharmaceuticalMicrobiome
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
85
By Phase
PHASE1/PHASE2: 2PHASE1: 1
By Status
RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06448572Collaborator
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
PHASE1/PHASE2Recruiting
21 participants
Started: Jul 16, 2024 · Completed: Oct 1, 2028
NCT06306014Collaborator
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
PHASE1/PHASE2Recruiting
56 participants
Started: May 7, 2024 · Completed: Jan 7, 2027
NCT05542355Lead Sponsor
EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
PHASE1Terminated
8 participants
Started: Mar 20, 2023 · Completed: Oct 2, 2024
Locations (1)
Headquarters
Dijon, France
Map
Loading map...